Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of the intranasal influenza virus vector COVID-19 vaccine DelNS1-2019-nCoV-RBD-OPT1
ChiCTR2100051391Phase 3Completed
- Sponsor
- N/A
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of Pneucolin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by N/A. Primary endpoints: First RT-PCR-confirmed symptomatic COVID-19 of any severity at least 15 days after second vaccination, Serious adverse events, medically attended adverse events, and adverse events of special interest and 2 more. Started Dec 2021; status: completed.
02
Drugs
Pneucolin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100051391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051391.